Group 1 - Doximity reported quarterly earnings of $0.36 per share, exceeding the Zacks Consensus Estimate of $0.31 per share, and showing an increase from $0.28 per share a year ago, resulting in an earnings surprise of +16.13% [1] - The company achieved revenues of $145.91 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 4.47%, and up from $126.68 million year-over-year [2] - Doximity has consistently outperformed consensus EPS and revenue estimates over the last four quarters [2] Group 2 - The stock has gained approximately 8.9% since the beginning of the year, compared to the S&P 500's gain of 7.9% [3] - The future performance of Doximity's stock will largely depend on management's commentary during the earnings call and the outlook for earnings estimates [3][4] - The current consensus EPS estimate for the upcoming quarter is $0.35 on revenues of $150.43 million, and for the current fiscal year, it is $1.46 on revenues of $625.72 million [7] Group 3 - The Medical Info Systems industry, to which Doximity belongs, is currently ranked in the top 37% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Doximity's stock performance [5][6]

Company Performance - Nerdy Inc. reported a quarterly loss of $0.07 per share, better than the Zacks Consensus Estimate of a loss of $0.10, and an improvement from a loss of $0.08 per share a year ago, resulting in an earnings surprise of +30.00% [1] - The company posted revenues of $45.26 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 3.04%, and down from $50.98 million year-over-year [2] - Over the last four quarters, Nerdy has surpassed consensus EPS estimates four times and topped consensus revenue estimates three times [2] Future Outlook - The current consensus EPS estimate for the coming quarter is -$0.12 on revenues of $42.34 million, and for the current fiscal year, it is -$0.33 on revenues of $193.8 million [7] - The estimate revisions trend for Nerdy was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Schools industry, to which Nerdy belongs, is currently in the top 15% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% of industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5]

Financial Performance - BioLife Solutions, Inc. (BLFS) reported break-even quarterly earnings per share, surpassing the Zacks Consensus Estimate of a loss of $0.02, and improved from a loss of $0.06 per share a year ago, representing an earnings surprise of +100.00% [1] - The company posted revenues of $25.42 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 6.98%, although this is a decline from year-ago revenues of $28.33 million [2] - Over the last four quarters, BioLife Solutions has consistently surpassed consensus EPS and revenue estimates [2] Stock Performance and Outlook - BioLife Solutions shares have declined approximately 18.8% since the beginning of the year, contrasting with the S&P 500's gain of 7.9% [3] - The company's future stock performance will largely depend on management's commentary during the earnings call and the earnings outlook [4][6] - The current consensus EPS estimate for the upcoming quarter is -$0.02 on revenues of $24.55 million, and for the current fiscal year, it is $0.02 on revenues of $97.83 million [7] Industry Context - The Medical - Products industry, to which BioLife Solutions belongs, is currently ranked in the bottom 37% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact investor sentiment [5]

Company Performance - Ascend Wellness Holdings, Inc. reported a quarterly loss of $0.12 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.07, representing an earnings surprise of -71.43% [1] - The company posted revenues of $127.3 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 0.93% and down from $141.54 million a year ago [2] - Over the last four quarters, the company has only surpassed consensus EPS estimates once and has not beaten consensus revenue estimates [2] Stock Movement and Outlook - Ascend Wellness Holdings, Inc. shares have increased approximately 20.5% since the beginning of the year, outperforming the S&P 500's gain of 7.9% [3] - The company's future stock performance will largely depend on management's commentary during the earnings call and the earnings outlook [3][4] - The current consensus EPS estimate for the upcoming quarter is -$0.07 on revenues of $132.15 million, and for the current fiscal year, it is -$0.27 on revenues of $527.85 million [7] Industry Context - The Medical Services industry, to which Ascend Wellness Holdings, Inc. belongs, is currently ranked in the top 40% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact the stock's performance [5][6]

Core Viewpoint - Prime Medicine, Inc. reported a quarterly loss of $0.41 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.36, representing an earnings surprise of -13.89% [1][2] Financial Performance - The company posted revenues of $1.12 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 59.6%, compared to zero revenues a year ago [2] - Over the last four quarters, Prime Medicine has surpassed consensus EPS estimates only once [2] Stock Performance - Prime Medicine shares have increased by approximately 39.4% since the beginning of the year, outperforming the S&P 500's gain of 7.9% [3] Future Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.29 on revenues of $2.59 million, and for the current fiscal year, it is -$1.30 on revenues of $7.74 million [7] - The estimate revisions trend for Prime Medicine was favorable ahead of the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Prime Medicine belongs, is currently in the top 41% of over 250 Zacks industries, suggesting a favorable outlook for stocks in this sector [8]

分组1 - Kelly Services reported quarterly earnings of $0.54 per share, matching the Zacks Consensus Estimate, but down from $0.71 per share a year ago [1] - The company posted revenues of $1.1 billion for the quarter ended June 2025, missing the Zacks Consensus Estimate by 1.86%, compared to $1.06 billion in the same quarter last year [2] - The stock has underperformed, losing about 12.1% since the beginning of the year, while the S&P 500 gained 7.9% [3] 分组2 - The earnings outlook for Kelly Services is mixed, with the current consensus EPS estimate for the coming quarter at $0.43 on revenues of $1.07 billion, and $2.11 on revenues of $4.54 billion for the current fiscal year [7] - The Zacks Industry Rank indicates that the Staffing Firms industry is in the bottom 21% of over 250 Zacks industries, which may impact stock performance [8] - Korn/Ferry, another company in the same industry, is expected to report quarterly earnings of $1.24 per share, reflecting a year-over-year change of +5.1% [9]

Core Insights - Intellia Therapeutics reported a quarterly loss of $0.99 per share, which was better than the Zacks Consensus Estimate of a loss of $1.03, and an improvement from a loss of $1.31 per share a year ago, resulting in an earnings surprise of +3.88% [1] - The company achieved revenues of $14.25 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 9.43%, and showing significant growth from $6.96 million in the same quarter last year [2] - Intellia Therapeutics has consistently surpassed consensus EPS estimates over the last four quarters, indicating a positive trend in performance [2] Company Performance - The stock has underperformed the market, losing about 2.5% since the beginning of the year, while the S&P 500 has gained 7.9% [3] - The current consensus EPS estimate for the upcoming quarter is -$1.03 on revenues of $13.39 million, and for the current fiscal year, it is -$4.24 on revenues of $57.71 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Intellia Therapeutics belongs, is currently ranked in the top 41% of over 250 Zacks industries, suggesting a favorable industry outlook [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Intellia's stock performance [5][6]

Group 1: Earnings Performance - Papa John's reported quarterly earnings of $0.41 per share, exceeding the Zacks Consensus Estimate of $0.34 per share, but down from $0.61 per share a year ago, representing an earnings surprise of +20.59% [1] - The company posted revenues of $529.17 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 2.68% and up from $507.89 million year-over-year [2] - Over the last four quarters, Papa John's has consistently surpassed consensus EPS estimates [2] Group 2: Stock Performance and Outlook - Papa John's shares have declined approximately 1.3% since the beginning of the year, while the S&P 500 has gained 7.9% [3] - The company's current consensus EPS estimate for the upcoming quarter is $0.42 on revenues of $525.11 million, and for the current fiscal year, it is $1.74 on revenues of $2.11 billion [7] - The Zacks Rank for Papa John's is currently 3 (Hold), indicating expected performance in line with the market in the near future [6] Group 3: Industry Context - The Retail - Restaurants industry, to which Papa John's belongs, is currently ranked in the bottom 31% of over 250 Zacks industries, suggesting potential challenges ahead [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact investor sentiment [5]

Company Performance - Vital Farms reported quarterly earnings of $0.36 per share, exceeding the Zacks Consensus Estimate of $0.27 per share, with an earnings surprise of +33.33% [1] - The company achieved revenues of $184.77 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 9.10%, compared to $147.39 million in the same quarter last year [2] - Over the last four quarters, Vital Farms has consistently surpassed consensus EPS estimates four times and topped revenue estimates three times [2] Market Position - Vital Farms shares have underperformed the market, losing about 1% since the beginning of the year, while the S&P 500 has gained 7.9% [3] - The current Zacks Rank for Vital Farms is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.26 on revenues of $186.38 million, and for the current fiscal year, it is $1.26 on revenues of $743.6 million [7] - The outlook for the industry, specifically the Food - Miscellaneous sector, is currently in the bottom 23% of over 250 Zacks industries, which may impact the stock's performance [8]

Company Performance - Akebia Therapeutics reported break-even quarterly earnings per share, surpassing the Zacks Consensus Estimate of a loss of $0.02, and improved from a loss of $0.04 per share a year ago, resulting in an earnings surprise of +100.00% [1] - The company posted revenues of $62.47 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 33.50%, compared to year-ago revenues of $43.65 million [2] - Over the last four quarters, Akebia has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Performance - Akebia Therapeutics shares have increased approximately 99.2% since the beginning of the year, significantly outperforming the S&P 500's gain of 7.9% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.03 on revenues of $46.52 million, and for the current fiscal year, it is -$0.05 on revenues of $199.75 million [7] Industry Outlook - The Medical - Drugs industry, to which Akebia belongs, is currently ranked in the top 35% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that the industry outlook can materially impact stock performance [5][8]